⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4564742 | 0.98 | PIM1 (0.49) | — | |
| SCHEMBL4557713 | 0.87 | PIM1 (0.41) | — | |
| SCHEMBL929848 | 0.81 | PIM1 (0.51) | — | |
| SCHEMBL2898099 | 0.81 | — | — | |
| Methylamine SCHEMBL27814550 | 0.80 | PIM1 (0.47) | — | |
| SCHEMBL17152822 | 0.79 | — | — | |
| SCHEMBL929849 | 0.79 | PIM1 (0.50) | — | |
| SCHEMBL11358876 | 0.79 | — | — | |
| SCHEMBL15124917 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL20557184 | 0.78 | PIM1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000870-A1 | Pharmaceutical Combinations for Treating Cancer | CELLESTIA BIOTECH AG (CH) | 2025-01-02 | — | — | US | disclosed |
| EP-4429661-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | Cellestia Biotech AG (CH) | 2024-09-18 | — | — | EP | disclosed |
| EP-4277706-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023079132-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | CELLESTIA BIOTECH AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022154664-A1 | INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-07-21 | — | — | WO | disclosed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3773576-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019191112-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | disclosed |
| CN-103918661-B | The method of Fungicidal composition and control harmful fungoid | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2016-05-11 | — | — | CN | disclosed |
| EP-2073807-A1 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| EP-2049119-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3-[3-(5-MORPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL)-1H-1-PYRAZOL-4-YL]-UREA | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| EP-2043635-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001115-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3- (5-M0RPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL) -LH-1-PYRAZOL- 4-YL] -UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1833819-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |